Back to today’s briefing

Story perspectives

Revolutionary Implant PER-001 Offers Hope for Glaucoma Treatment

4/25/2025

33 7

Summary

Story summary

Perfuse Therapeutics is making strides with PER-001, a groundbreaking implant targeting glaucoma. Early trials reveal its potential to restore vision and enhance optic nerve health. With an adaptive Phase 2b trial set for Q4 2025, hopes are high for PER-001 to become a transformative treatment for this debilitating disease.

1 of 1

Story summary

Perfuse Therapeutics is making strides with PER-001, a groundbreaking implant targeting glaucoma. Early trials reveal its potential to restore vision and enhance optic nerve health. With an adaptive Phase 2b trial set for Q4 2025, hopes are high for PER-001 to become a transformative treatment for this debilitating disease.